Lung cancer is one of the most common and serious types of cancer, with around 44,500 new cases of the disease diagnosed in the UK each year.
Symptoms of the disease are are usually present in the early stages, but many people will eventually develop symptoms as the condition progresses.
Common symptoms include a persistent cough that doesn’t go away after two or three weeks, a long-standing cough that gets worse, peristent chest infections and coughing up blood.
Oncimmune (LON:ONC) is a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer. Oncimmune is changing how clinicians, researchers and patients view, diagnose and treat cancer. Our technology detects evidence of the body’s natural response to cancer, enabling detection 4 years or more before standard clinical diagnosis. Our tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. We partner with leading developers and distributors to make our technology available globally.
